News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

E. Dühmke

Articles by E. Dühmke

2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD-Interim Ahan Radiotherapy Alone in Early Stage HD-Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/Germany

ByH. Tesch,M. Sieber,J. U. Rüffer,J. Franklin,R. Herrmann,F. Boissevain,A. Franke,M. Pfreundschuh,D. Hossfeld,E. Dühmke,J. Wolf,A. Engert,U. Paulus,V. Diehl

March 1st 1999

BACKGROUND: Extended-field radiotherapy is effective in patients with early-stage Hodgkin’s disease, and more than

Increased Efficacy Through Moderate Dose Escalation of Chemotherapy: Interim Report From the HD9 Randomized Trial for Advanced Hodgkin’s Disease

ByV. Diehl,J. Franklin,M. Sieber,D. Hasenclever,U. Paulus,H. Tesch,M. Pfreundschuh,U. Rüffer,R. Hermann,C. Longin,M. Hänel,G. Wulf,W. Aulitzky,A. Georgii,E. Dühmke,M. Loeffler

March 1st 1999

This report aims to assess the effect of increased drug dose on the efficacy and toxicity of the BEACOPP regimen with

Latest Updated Articles

2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD-Interim Ahan Radiotherapy Alone in Early Stage HD-Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/Germany
Published: March 1st 1999 | Updated:
Increased Efficacy Through Moderate Dose Escalation of Chemotherapy: Interim Report From the HD9 Randomized Trial for Advanced Hodgkin’s Disease
Published: March 1st 1999 | Updated:

Trending on CancerNetwork

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

FDA Grants Fast Track Designation to MT-125 in Glioblastoma

HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma

FDA Accepts NDA for New Nilotinib Formulation in CML

FDA Grants BTD to Zenocutuzumab in NRG1+ Cholangiocarcinoma

© 2025 MJH Life Sciences^®

All rights reserved.